Trial · NCT06597513
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
NCT06597513, Phase 1, Phase 2, Not yet recruiting, Zhou Chengzhi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC. Trials, record NCT06597513. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06597513
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
- NCT number
- NCT06597513
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Zhou Chengzhi
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab
- First posted
- 2024-09-19
- Last updated
- 2024-10-15
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0 | Time Frame: Followed up every 21 days. | Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0, detailed descriptions of the events, the onset timing, severity grade, therapeutic interventions undertaken, and the potential correlation with the investigational medication. |
| Secondary | Median Progression Free Survival (mPFS) | Imaging examination every 6 weeks. | The time of disease progression or death in 50% of patients according to K-M curve. |
| Secondary | 12-months OS rate | Followed up by telephone every 2 months | The percentage of patients survival in the 12th months according to the K-M curve. |
| Secondary | 24-months OS rate | Followed up by telephone every 2 months | The percentage of patients survival in the 24th months according to the K-M curve. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39848827 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06597513
GET https://conductscience.org/api/trials/v1/NCT06597513/registered